Translate this page into:
None
doi:
10.4103/2278-330X.175959
Palliative low dose fortnightly methotrexate in oral cancer
*Corresponding author: Prof. Sim Sai Tin. simsaitin@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Chakraborty S, Geetha M, Sujith KM, Biji MS, Sateeshan B. Palliative low dose fortnightly methotrexate in oral cancers: Experience at a rural cancer centre from India. South Asian J Cancer 2014;3:166-70.
- Jones WG, Fosså SD, Verbaeys AC, Droz JP, Klijn JG, Boven E, et al. Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur J Cancer 1990;26:646.
- Shiver MB, Hall LA, Conner KB, Brown GE, Cheung WL, Wirges ML. Cutaneous erosions: A herald for impending pancytopenia in methotrexate toxicity. Dermatol Online J 2014;20.
- Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 2014;41:1049-60.